Thermodynamic and kinetic origins of Alzheimer's and related diseases: A chemical engineer's perspective

AIChE Journal

Volumn 54, Issue 8, 2008, Pages 1956-1962

  Hall, Carol K ^a  

^a North Carolina State University   (United States)

Author keywords

Alzheimer's disease; Amyloid

Indexed keywords

EID: 49049098668     PISSN: 00011541     EISSN: 15475905     Source Type: Journal    
DOI: 10.1002/aic.11589     Document Type: Article

References (41)

1. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991;6:487-498.
2. Alzheimer A. Uber einen eigenartige Erkranung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtisch Medizin. 1907;64:146-148.
3. Alzheimer's Research Forum, Facts and Figures http://www.alzforum.org/ dis/abo/default.asp.
4. 2008 Alzheimer's Facts and Figures. Alzheimer's Association; 2008.www.alz.org.
5. Kelly JW. Towards an understanding of amyloidogenesis. Nat Struct Mol Biol. 2002;9:323-325.
6. Chiti F, Dobson CM. Protein misfolding, functional amyloid and human disease. Annu Rev Biochem. 2006;75:333-366.
7. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356.
8. Roberson ED, Mucke L. 100 years and counting: Prospects for defeating Alzheimer's disease. Science. 2006;314:781-784.
9. Hardy J. A hundred years of Alzheimer's research. Neuron. 2006;52:3-13.
10. Marx J. A new take on tau. Science. 2007;316:1416.
11. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol. 1997;273:729-739.
12. Makin OS.and Serpell LC. Structure for amyloid fibrils. FEBS J. 2005:272:5950-5961.
13. Burkoth. TS, Benzinger TLS, Urban V, Morgan DM, Gregory DM, Thiyagarajan P, Botto RE, Meredith SC, and Lynn DG. Structure of the β-amyloid (10-35) fibril. J Am Chem Soc. 2000;122:7883-7889.
14. Petkova AT, Ishii Y, Balbach JJ, Antuzutkin ON, Leapman RD, Delaglio F, and Tycko R. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci. 2002;99:16742-16747.
15. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tyco R. Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science. 2005;307:262-265.
16. Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochem. 2006;45:498-512.
17. Buchete NV, Tycko R, Hummer G. Molecular dynamics simulations of Alzheimer's beta-amyloid protofilaments. J Mol Biol. 2005;353:804-821.
18. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416;507-511.
19. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003:300:486-489.
20. Zhang S. Fabrication of novel biomaterials through molecular self assembly. Nature Biotechnol. 2003;21:1171-1178.
21. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang G-F, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004;55:306-319.
22. Hall CK, Nguyen HD, Marchut AJ, Wagoner V. Simulations of protein aggregation. In: Misbehaving Proteins: Protein Misfolding Aggregation and Stability. Murphy RM, Tsai AM, eds. Springer; 2006:47-77.
23. Ma B, Nussinov R. Stabilities and conformations of Alzheimer's beta amyloid peptide oligomers (A-beta 16-22, A-beta 16-35 and A-beta 10-35): sequence effects. Proc Natl Acad Sci USA. 2002:99:14126-14131.
24. Zheng J, Jang H, Ma B, Tsai C-J, Nussinov R. Modeling the Alzheimer Aβ 17-42 fibril architecture: tight intermolecular sheet-sheet association and intramolecular hydrated cavities. Biophys J. 2007;933046-933057.
25. Cellmer T, Bratko D, Prausnitz JM, Blanch HW. Protein aggregation in silico. Trends Biotechnol. 2007;25:254-261.
26. Cellmer T, Bratko D, Prausnitz JM, Blanch H. Protein folding landscapes in multichain systems. Proc Natl Acad Sci USA. 2005;102:11692-11697.
27. Bratko D, Cellmer T, Prasunitz JM, Blanch HW. Effect of single point sequence alterations on the aggregation propensity of a model protein. J Am Chem Soc. 2006;128:1683-1691.
28. Nguyen HD, Marchut AJ, Hall CK. Solvent effects on the conformational transition of model polyalanine peptides. Protein Sci. 2004;13:2909-2924.
29. Nguyen HD, Hall CK. Molecular dynamics simulations of spontaneous fibril formation by random coli peptides. Proc Natl Acad Sci USA. 2004;101:16180-16185.
30. Rochet JC, Lansbury PT. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol. 2000;10:60-68.
31. Pallitto M, Murphy MR. A mathematical model of the kinetics of β-Amyloid fibril growth from the denatured state. Biophys J. 2001;81:1805-1822.
32. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. J Biol Chem. 1997;272:22364-22372.
33. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous systems neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448-6453.
34. Roberts CJ.Nonnative protein aggregation: pathways, kinetics and stability prediction. In: In Misbehaving Proteins: Protein Misfolding Aggregation and Stability. Murphy RM, Tsai AM, eds. Springer; 2006:17-46.
35. Lansbury PT, Lashuel HA. A century -old debate on protein aggregation and neurodegeneration enters the clinic. Nature. 2006;443:774-779.
36. Lashuel HA and Lansbury PT. Are amyloid disease caused by protein aggregates that mimic bacterial pore forming toxins? Q Rev Biophys. 2006;39:167-201.
37. Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med. 2006;57:513-533.
38. Lee S, Carson K, Rice-Ficht A, Good T, Small heat shock proteins differentially affect Aβ aggregation and toxicity. Biochem Biophys Res Commun. 2006;347:527-533.
39. Gibson TJ, Murphy RM. Design of peptidyl compounds that affect β-amyloid aggregation: importance of surface tension and context. Biochem. 2005;44:8898-8907.
40. Necula M, Kayed R, Milton S, Glabe CG. Small molecular inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. J Biol Chem. 2007;282:10311-10324.
41. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, McLean PJ, Young AB, Houseman DE, Kazantsev AG. Pharmacological promotion of inclusion formation; a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci USA. 2006;103:4246-4251.